Related Experiment Video
Updated: Aug 3, 2025
04:34
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
1.1K
Does insomnia treatment prevent depression?
Elaine M Boland1,2, Jennifer R Goldschmied1, Philip R Gehrman1,2
1Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Sleep
|April 8, 2023
Summary
Treating insomnia with cognitive behavioral treatment for insomnia (CBT-I) may help prevent major depressive disorder (MDD) onset. Evidence suggests CBT-I reduces depression risk, though more research is needed.
Area of Science:
- Mental Health
- Neuroscience
- Public Health
Background:
- Major depressive disorder (MDD) rates are rising globally, exacerbated by the COVID-19 pandemic.
- Insomnia is a known risk factor for depression and is linked to increased severity and poorer treatment outcomes.
- Targeting insomnia treatment is a logical strategy for preventing new and recurrent episodes of MDD.
Approach:
- This systematic review evaluated existing evidence on the preventive effects of insomnia treatment on depression onset.
- A comprehensive database search identified 186 studies, with six meeting the inclusion criteria.
- All included studies focused on cognitive behavioral treatment for insomnia (CBT-I), often delivered digitally.
Key Points:
- Four of the six studies reported significantly lower rates of MDD onset in participants receiving CBT-I compared to control groups.
- The remaining two studies did not find significant preventive effects in primary analyses, but secondary analyses indicated potential benefits.
- Methodological heterogeneity across studies (sample selection, outcomes, follow-up) limits definitive conclusions.
Conclusions:
- The current evidence suggests a trend towards insomnia treatment, specifically CBT-I, reducing the risk of developing MDD.
- Further rigorous research is warranted to confirm these preventive effects and establish optimal treatment protocols.
- Digital delivery of CBT-I shows promise as a scalable intervention for MDD prevention.
Related Concept Videos
01:27Insomnia
111
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
111
01:19Management of Insomnia
292
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
292
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
210
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
210
01:23Antidepressant Drugs: MAOIs and Other Agents
288
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
288
01:14CNS Depressants: Barbiturates and Benzodiazepines
373
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
373
01:13Insufficient Sleep and Sleep Deprivation
189
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
189